CLINICAL TRIALS PROFILE FOR SODIUM TETRADECYL SULFATE
✉ Email this page to a colleague
All Clinical Trials for SODIUM TETRADECYL SULFATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01347294 ↗ | Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations | Unknown status | Oslo University Hospital | Phase 4 | 2011-08-01 | The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation. |
NCT01408732 ↗ | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Completed | American Rhinologic Society | Phase 1/Phase 2 | 2011-02-01 | The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease. |
NCT01408732 ↗ | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Completed | University of Minnesota | Phase 1/Phase 2 | 2011-02-01 | The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease. |
NCT01408732 ↗ | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 1/Phase 2 | 2011-02-01 | The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease. |
NCT03311269 ↗ | A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency | Recruiting | Vascular Insights, LLC | Phase 2 | 2017-09-22 | VICARES is a prospective randomized, controlled, multi-center, double blind study treating venous insufficiency associated with incompetent saphenous veins with 1% and 3% Sodium Tetradecyl Sulfate (STS) solution utilizing the ClariVein system. |
NCT03363633 ↗ | Perforator Vein Injection for Symptomatic Venous Disease | Terminated | American College of Phlebology | N/A | 2010-03-01 | The primary objective of this study is to compare two treatment strategies for symptomatic venous stasis disease with and without venous ulcer. These treatments are compression therapy alone vs. sclerotherapy of refluxing perforating veins with compression. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SODIUM TETRADECYL SULFATE
Condition Name
Clinical Trial Locations for SODIUM TETRADECYL SULFATE
Trials by Country
Clinical Trial Progress for SODIUM TETRADECYL SULFATE
Clinical Trial Phase
Clinical Trial Sponsors for SODIUM TETRADECYL SULFATE
Sponsor Name